Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOSABEMA pharmacokinetic model of abemaciclib and severe diarrhea in hormone receptor-positive localized breast cancer
2025-521696-31-00Phase 4Authorised
- Sponsor
- CHU de Poitiers
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abemaciclib in breast cancer, sponsored by CHU de Poitiers. Primary endpoint: Severe diarrhea probability related to abemaciclib exposure. Planned start Jan 2026; status: authorised.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-521696-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521696-31-00.